Free Trial
NASDAQ:EVFM

Evofem Biosciences (EVFM) Stock Price, News & Analysis

Evofem Biosciences logo
$0.0082 0.00 (-15.46%)
As of 04/7/2025 03:47 PM Eastern

About Evofem Biosciences Stock (NASDAQ:EVFM)

Key Stats

Today's Range
$0.0082
$0.01
50-Day Range
$0.0073
$0.01
52-Week Range
$0.01
$0.02
Volume
197,499 shs
Average Volume
596,257 shs
Market Capitalization
$929,519.20
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evofem Biosciences, Inc., is a small biopharmaceutical company with a single commercial product as well as a pipeline of potential winners. The company works to develop and commercialize a variety of product lines intended to address unmet needs in women’s sexual and reproductive health. The company’s motto is Science With A Soul and its aim is to improve women’s lives with innovative solutions. In fact, the sole purpose of the company is to improve the quality of women’s lives by enabling greater control of their healthcare needs.

Evofem Biosciences went public in January 2018. The company is headquartered in San Diego, California, and is led by Saundra Pelletier. Ms. Pelletier has been CEO, president, and executive director of the company since February 2015 and is instrumental in the company’s transition to a publicly traded issue. Ms. Pelletier has more than 25 years of experience in the pharmaceutical industry and is responsible for launching and expanding the use of many brands.

Evofem’s primary commercial product is Phexxi. Phexxi is a vaginal gel for the prevention of pregnancy. Phexxi is the US first and only hormone-free prescription birth control product that is controlled by the individual. It stands out from other methods because it is hormone free, requires no daily usage, comes with no invasive procedures, and is easy to carry in a bag and use when needed.

Phexxi works by maintaining vaginal pH after intercourse and relies on 3 naturally occurring chemicals that are regularly found in food: lactic acid, citric acid, and potassium bitartrate (cream of tartar for the chefs out there). The product works because sperm need a higher pH to thrive than what is normal in women’s health and that is provided by the semen. Phexxi’s acidic composition is formulated to maintain the ideal pH and keep the sperm inactive. Phexxi can also block the cervical opening and prevent sperm from entering.

Among the many advantages of Phexxi are reduced or non-existent side effects as compared to other forms of birth control which include mood swings, headaches, and irritability. The product is approved by the FDA and prescriptions can be filled via telehealth appointment. The company estimates each 100 basis points of US market share it can secure is worth $300 million in annual revenue.

The opportunity for Evofem is that its product, Phexxi, has been shown to be effective in fighting the transmission of gonorrhea and chlamydia. The transmission of both STDs has been associated with higher pH levels which Phexxi is specifically fighting. The investigational drug EV-100 (Phexxi) has made it through to Phase 3 clinical testing and regulatory filings are expected. The company also has two other products in development and they are on track to enter clinical trials.

 

Remove Ads

Evofem Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

EVFM MarketRank™: 

Evofem Biosciences scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Evofem Biosciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evofem Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evofem Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for EVFM.
  • Dividend Yield

    Evofem Biosciences does not currently pay a dividend.

  • Dividend Growth

    Evofem Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for EVFM.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Evofem Biosciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Evofem Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.21% of the stock of Evofem Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 0.22% of the stock of Evofem Biosciences is held by institutions.

  • Read more about Evofem Biosciences' insider trading history.
Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVFM Stock News Headlines

10X Bigger than AI, quantum, EVs, crypto, and robotics combined?
World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and Mark Zuckerberg are all investing vast sums of money into a radical technology. According to Bloomberg, this could become 10 times bigger than AI, quantum computing, electric vehicles, cryptocurrencies, and robotics combined. And one stock is at the center of it all.
See More Headlines

EVFM Stock Analysis - Frequently Asked Questions

Evofem Biosciences' stock was trading at $0.0099 at the start of the year. Since then, EVFM shares have decreased by 17.2% and is now trading at $0.0082.
View the best growth stocks for 2025 here
.

Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its quarterly earnings data on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company had revenue of $5.81 million for the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%.

Evofem Biosciences shares reverse split before market open on Thursday, May 18th 2023. The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F).

Company Calendar

Last Earnings
6/16/2023
Today
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EVFM
Employees
120
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$52.98 million
Pretax Margin
-46.42%

Debt

Sales & Book Value

Annual Sales
$11.39 million
Price / Cash Flow
N/A
Book Value
($2.64) per share
Price / Book
0.00

Miscellaneous

Free Float
113,118,000
Market Cap
$929,519.20
Optionable
Not Optionable
Beta
-0.87

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:EVFM) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners